Antibody Drug Conjugates (ADC)

Antibody Drug Conjugates (ADC)

Antibody Drug Conjugates (ADC) is a type of biopharmaceutical drug that combines a monoclonal antibody with a drug to treat cancer. ADCs are composite of three components: A monoclonal antibody that binds to specific proteins on cancer cells, A chemical linker that joins the antibody to the drug, and the drug payload that is released inside the cancer cell to kill it. Unlike chemotherapy, ADCs are designed to target cancer cells while minimizing damage to healthy cells.

A list of FDA approved and clinical trial ADCs are provided as a reference for customer's new ADC research & development. These ADC references can be used as a positive control for in vitro and in vivo studies.

Catalog Product Name M.W. Purity Pricing
Antibody Drug Conjugates (ADC)
BP-50167Trastuzumab-MMAE~148kDa>98%Pricing
BP-50168Trastuzumab-MMAF~148kDa>98%Pricing
BP-50169Ado-Trastuzumab emtansine (KADCYLA®)~148kDa>98%Pricing
BP-50170Trastuzumab-DM4~148kDa>98%Pricing
BP-50171Trastuzumab-Calicheamicin~148kDa>98%Pricing
BP-50172Fam-Trastuzumab deruxtecan-nxki (ENHERTU®)~148kDa>98%Pricing
BP-50173Trastuzumab-SN38~148kDa>98%Pricing
BP-50188Sacituzumab govitecan160kDa98%Pricing
BP-50190Datopotamab deruxtecan146kDa98%Pricing
BP-50191Ifinatamab deruxtecan153kDa98%Pricing
BP-50192Cofetuzumab pelidotin151.7kDa99%Pricing
BP-50193Disitamab vedotin149kDa99%Pricing
BP-50194Mirvetuximab soravtansine150kDa99%Pricing
BP-50196Patritumab deruxtecan158kDa91%Pricing
BP-50197Enfortumab vedotin-ejfv152kDa99%Pricing
BP-50198Belantamab mafodotin152kDa99%Pricing
BP-50201Telisotuzumab vedotinN/A99%Pricing
BP-50202Brentuximab vedotin153kDa99%Pricing
BP-50203Tusamitamab ravtansine148kDa99%Pricing
BP-50205Polatuzumab vedotin150kDa99%Pricing
BP-50206Labetuzumab govitecan154kDa99%Pricing
BP-50207Loncastuximab tesirine151kDa99%Pricing
BP-50208Tisotumab vedotin153kDa99%Pricing
BP-50210Farletuzumab ecteribulin149kDa99%Pricing
BP-50211Glembatumumab vedotin63.92KDa99%Pricing
BP-50212Trastuzumab duocarmazine145KDa99%Pricing
BP-50213Zilovertamab vedotin145KDa99%Pricing
BP-50214Cantuzumab ravtansineN/A99%Pricing
BP-50215Depatuxizumab MafodotinN/A98%Pricing
BP-50216Sofituzumab Vedotin155 kDa98%Pricing
BP-50217Azintuxizumab vedotinN/A98%Pricing
BP-50218Depatuxizumab MMAE148kDaN/APricing
BP-50221Cantuzumab mertansine145kDa99%Pricing
BP-50289Trastuzumab-NH-PEG8-VC-PAB-MMAE~150kDa>98%Pricing